Donafenib extends OS in advanced liver cancer

Donafenib conferred a modest but statistically significant OS improvement as first-line therapy for advanced hepatocellular carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.The novel multikinase inhibitor also exhibited a favorable safety and tolerability profile, results of the randomized phase 2/phase 3 trial showed.“Hepatocellular carcinoma is characterized by an insidious onset with rapid progression,” Feng Bi, MD, oncologist at West China Hospital at Sichuan University in China, said during a presentation. “Many patientsRead More

Share on facebook
Share on twitter
Share on linkedin